NR3C2 and acute kidney injury: Since the combination of ACEI and ARB did not provide more beneficial effects than monotherapy and instead increased the risk of hyperkalemia and acute kidney injury (AKI), the enthusiasm for enhanced RAAS blockade shifted to combining mineralocorticoid receptor antagonists (MRAs) with RAAS inhibitors [55].